Shares of Humanigen, Inc. (NASDAQ:HGEN – Get Rating) have been assigned a consensus rating of "Hold" from the seven ratings firms that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $19.50.
A number of analysts recently weighed in on the company. Cantor Fitzgerald downgraded Humanigen from an "overweight" rating to a "neutral" rating in a report on Wednesday, July 13th. Credit Suisse Group downgraded Humanigen from a "neutral" rating to an "underperform" rating in a report on Wednesday, July 13th. HC Wainwright downgraded Humanigen from a "buy" rating to a "neutral" rating in a report on Wednesday, July 13th. Finally, Roth Capital downgraded Humanigen from a "buy" rating to a "neutral" rating in a report on Wednesday, July 13th.
Get
Humanigen alerts:
Insiders Place Their Bets
In related news, insider Dale Chappell acquired 545,488 shares of the business's stock in a transaction dated Friday, May 20th. The shares were bought at an average price of $2.23 per share, with a total value of $1,216,438.24. Following the transaction, the insider now directly owns 8,675,081 shares of the company's stock, valued at $19,345,430.63. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 21.70% of the company's stock.
Hedge Funds Weigh In On Humanigen
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE boosted its position in shares of Humanigen by 262.2% during the 1st quarter. Bank of America Corp DE now owns 328,404 shares of the company's stock worth $988,000 after purchasing an additional 237,743 shares in the last quarter. Virtu Financial LLC lifted its position in Humanigen by 71.3% in the 1st quarter. Virtu Financial LLC now owns 37,463 shares of the company's stock valued at $113,000 after acquiring an additional 15,588 shares in the last quarter. State Street Corp lifted its position in Humanigen by 31.7% in the 1st quarter. State Street Corp now owns 1,246,922 shares of the company's stock valued at $3,753,000 after acquiring an additional 300,345 shares in the last quarter. Frontier Wealth Management LLC bought a new position in Humanigen in the 1st quarter valued at about $155,000. Finally, XTX Topco Ltd bought a new position in Humanigen in the 1st quarter valued at about $111,000. Institutional investors own 64.34% of the company's stock.
Humanigen Stock Performance
Shares of NASDAQ:HGEN opened at $0.49 on Wednesday. The company has a fifty day moving average of $2.09 and a 200-day moving average of $2.43. The company has a market capitalization of $34.68 million, a PE ratio of -0.15 and a beta of -0.79. Humanigen has a 52-week low of $0.47 and a 52-week high of $18.65.
Humanigen (NASDAQ:HGEN – Get Rating) last announced its quarterly earnings results on Thursday, May 5th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.17. The company had revenue of $1.04 million during the quarter, compared to the consensus estimate of $1.04 million. Humanigen had a negative net margin of 4,640.77% and a negative return on equity of 4,882.88%. On average, equities analysts forecast that Humanigen will post -0.91 EPS for the current fiscal year.
Humanigen Company Profile
(Get Rating)
Humanigen, Inc, a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called 'cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH.
Further Reading
- Get a free copy of the StockNews.com research report on Humanigen (HGEN)
- Financial services firm Block stock has fallen (-59%) in 2022
- Hold Pfizer Today With Catalysts for Further Growth Tomorrow
- NVIDIA Stock is a Winding Up for a Record Setting Second Half
- Johnson & Johnson Continues to Prove its Value in a Volatile Year
- MarketBeat: Week in Review 7/11 – 7/15
Receive News & Ratings for Humanigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humanigen and related companies with MarketBeat.com's FREE daily email newsletter.
